{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:30:43Z","timestamp":1791862243229,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1KL2TR001411"],"award-info":[{"award-number":["1KL2TR001411"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1TR001430"],"award-info":[{"award-number":["1UL1TR001430"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alcohol Withdrawal Syndrome occurs in 1 in 43 hospitalized patients and is associated with increased morbidity. Pharmacotherapy for patients hospitalized with alcohol withdrawal syndrome are incompletely described. Understanding current practice patterns is essential to improving outcomes and addressing variability in care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify alcohol withdrawal syndrome treatment practice patterns across United States hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Multicenter retrospective cohort study with data collected between quarter 1 of 2016 and quarter 3 of 2022 using Premier Incorporated Artificial Intelligence Healthcare Database (~\u200925% of United States hospital admissions; excludes emergency room care).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 245,271 adult inpatients with a primary diagnosis of alcohol withdrawal syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Measures<\/jats:title>\n                    <jats:p>The outcomes were alcohol withdrawal syndrome medication treatment patterns, including initial treatment regimens, dosage trends, and factors associated with medication choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>Among 245,271 patients with alcohol withdrawal syndrome, 226,816 [92.5%] received benzodiazepines, 28,123 (11.5%) phenobarbital, and 113,746 (46.4%) other AWS agents within the first five days of admission. The most common initial treatment regimens were benzodiazepines alone (56.0%), benzodiazepines and other agents together (22.2%), and benzodiazepines and phenobarbital together (3.8%). Median daily benzodiazepine dose (diazepam equivalents) peaked on hospital day 2 (46.2 [interquartile range 23.1\u201384.2] mg), whereas median daily phenobarbital dose peaked on hospital day 1 (260 [120\u2013520] mg). Type of medication used was associated with level of care at admission, hospital facility, and United States geographical region. In adjusted analyses, the admission hospital was associated with phenobarbital use (median odds ratio 4.21 [95% confidence interval 4.03\u20134.40]), benzodiazepine use (median odds ratio 3.09 [2.96\u20133.23]) and other agents (median odds ratio 1.65 [1.62\u20131.67]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Alcohol withdrawal syndrome treatment varied by level of care at admission and hospital, highlighting significant variability in practice patterns. These findings inform future trials comparing the effectiveness of different medication regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-09817-8","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:05:29Z","timestamp":1756397129000},"page":"1058-1068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological Interventions for Alcohol Withdrawal Syndrome Among Hospitalized Adults: A Multicenter Cohort Study"],"prefix":"10.1007","volume":"41","author":[{"given":"Brody A.","family":"Erfle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Steel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anica C.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Hills-Dunlap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Afshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Walkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten E.","family":"Austad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari-Lynn","family":"Drainoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7161-5254","authenticated-orcid":false,"given":"Nicholas A.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"10","key":"9817_CR1","doi-asserted-by":"publisher","first-page":"e2438128","DOI":"10.1001\/jamanetworkopen.2024.38128","volume":"7","author":"TL Steel","year":"2024","unstructured":"Steel TL, Matson TE, Hallgren KA, et al. Incidence of Hospitalizations Involving Alcohol Withdrawal Syndrome in a Primary Care Population. JAMA Netw Open. 2024;7(10):e2438128. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.38128","journal-title":"JAMA Netw Open."},{"key":"9817_CR2","unstructured":"Robert S Hoffman, Gerald L Weinhouse. Management of moderate and severe alcohol withdrawal syndromes. In: UpToDate. Wolters Kluwer; 2023. Accessed January 4, 2024. https:\/\/www.uptodate.com\/contents\/management-of-moderate-and-severe-alcohol-withdrawal-syndromes"},{"key":"9817_CR3","unstructured":"Newman RK, Stobart Gallagher MA, Gomez AE. Alcohol Withdrawal. In: StatPearls. StatPearls Publishing; 2023. Accessed January 4, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441882\/"},{"issue":"9","key":"9817_CR4","doi-asserted-by":"publisher","first-page":"VE01","DOI":"10.7860\/JCDR\/2015\/13407.6538","volume":"9","author":"A Sachdeva","year":"2015","unstructured":"Sachdeva A, Choudhary M, Chandra M. Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. J Clin Diagn Res JCDR. 2015;9(9):VE01-VE07. https:\/\/doi.org\/10.7860\/JCDR\/2015\/13407.6538","journal-title":"J Clin Diagn Res JCDR."},{"key":"9817_CR5","doi-asserted-by":"publisher","unstructured":"The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020;14(3S):1-72. https:\/\/doi.org\/10.1097\/ADM.0000000000000668","DOI":"10.1097\/ADM.0000000000000668"},{"issue":"5","key":"9817_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-014-0163-5","volume":"28","author":"EC Perry","year":"2014","unstructured":"Perry EC. Inpatient Management of Acute Alcohol Withdrawal Syndrome. CNS Drugs. 2014;28(5):401-410. https:\/\/doi.org\/10.1007\/s40263-014-0163-5","journal-title":"CNS Drugs."},{"issue":"10","key":"9817_CR7","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1513\/AnnalsATS.202102-121OC","volume":"18","author":"NA Bosch","year":"2021","unstructured":"Bosch NA, Crable EL, Ackerbauer KA, et al. Implementation of a Phenobarbital-based Pathway for Severe Alcohol Withdrawal: A Mixed-Method Study. Ann Am Thorac Soc. 2021;18(10):1708-1716. https:\/\/doi.org\/10.1513\/AnnalsATS.202102-121OC","journal-title":"Ann Am Thorac Soc."},{"issue":"9","key":"9817_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.202203-0466LE","volume":"206","author":"NA Bosch","year":"2022","unstructured":"Bosch NA, Law AC, Walkey AJ. Phenobarbital for Severe Alcohol Withdrawal Syndrome: A Multicenter Retrospective Cohort Study. Am J Respir Crit Care Med. 2022;206(9):1171-1174. https:\/\/doi.org\/10.1164\/rccm.202203-0466LE","journal-title":"Am J Respir Crit Care Med."},{"issue":"4","key":"9817_CR9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ajem.2009.10.010","volume":"29","author":"GW Hendey","year":"2011","unstructured":"Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. Am J Emerg Med. 2011;29(4):382-385. https:\/\/doi.org\/10.1016\/j.ajem.2009.10.010","journal-title":"Am J Emerg Med."},{"issue":"3","key":"9817_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jemermed.2012.07.056","volume":"44","author":"J Rosenson","year":"2013","unstructured":"Rosenson J, Clements C, Simon B, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med. 2013;44(3):592-598.e2. https:\/\/doi.org\/10.1016\/j.jemermed.2012.07.056","journal-title":"J Emerg Med."},{"key":"9817_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajem.2023.04.002","volume":"69","author":"A Pourmand","year":"2023","unstructured":"Pourmand A, AlRemeithi R, Kartiko S, Bronstein D, Tran QK. Evaluation of phenobarbital based approach in treating patient with alcohol withdrawal syndrome: A systematic review and meta-analysis. Am J Emerg Med. 2023;69:65-75. https:\/\/doi.org\/10.1016\/j.ajem.2023.04.002","journal-title":"Am J Emerg Med."},{"key":"9817_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcrc.2015.11.022","volume":"32","author":"Y Mo","year":"2016","unstructured":"Mo Y, Thomas MC, Karras GE. Barbiturates for the treatment of alcohol withdrawal syndrome: A systematic review of clinical trials. J Crit Care. 2016;32:101-107. https:\/\/doi.org\/10.1016\/j.jcrc.2015.11.022","journal-title":"J Crit Care."},{"issue":"5","key":"9817_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/acem.14911","volume":"31","author":"B Borgundvaag","year":"2024","unstructured":"Borgundvaag B, Bellolio F, Miles I, et al. Guidelines for Reasonable and Appropriate Care in the Emergency Department (GRACE-4): Alcohol use disorder and cannabinoid hyperemesis syndrome management in the emergency department. Acad Emerg Med Off J Soc Acad Emerg Med. 2024;31(5):425-455. https:\/\/doi.org\/10.1111\/acem.14911","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med."},{"issue":"5","key":"9817_CR14","first-page":"A4807","volume":"61","author":"K Lorentzen","year":"2014","unstructured":"Lorentzen K, Lauritsen A\u00d8, Bendtsen AO. Use of propofol infusion in alcohol withdrawal-induced refractory delirium tremens. Dan Med J. 2014;61(5):A4807.","journal-title":"Dan Med J."},{"issue":"8","key":"9817_CR15","doi-asserted-by":"publisher","first-page":"e768","DOI":"10.1097\/CCM.0000000000003204","volume":"46","author":"AF Pizon","year":"2018","unstructured":"Pizon AF, Lynch MJ, Benedict NJ, et al. Adjunct Ketamine Use in the Management of Severe Ethanol Withdrawal. Crit Care Med. 2018;46(8):e768-e771. https:\/\/doi.org\/10.1097\/CCM.0000000000003204","journal-title":"Crit Care Med."},{"issue":"3","key":"9817_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/00003246-199603000-00009","volume":"24","author":"CD Spies","year":"1996","unstructured":"Spies CD, Dubisz N, Neumann T, et al. Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Crit Care Med. 1996;24(3):414-422. https:\/\/doi.org\/10.1097\/00003246-199603000-00009","journal-title":"Crit Care Med."},{"issue":"1","key":"9817_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2110-5820-2-12","volume":"2","author":"SG Rayner","year":"2012","unstructured":"Rayner SG, Weinert CR, Peng H, Jepsen S, Broccard AF, Study Institution. Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care. 2012;2(1):12. https:\/\/doi.org\/10.1186\/2110-5820-2-12","journal-title":"Ann Intensive Care."},{"issue":"2","key":"9817_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jcrc.2013.11.016","volume":"29","author":"EN Frazee","year":"2014","unstructured":"Frazee EN, Personett HA, Leung JG, Nelson S, Dierkhising RA, Bauer PR. Influence of dexmedetomidine therapy on the management of severe alcohol withdrawal syndrome in critically ill patients. J Crit Care. 2014;29(2):298-302. https:\/\/doi.org\/10.1016\/j.jcrc.2013.11.016","journal-title":"J Crit Care."},{"issue":"1","key":"9817_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1081\/ada-100100597","volume":"26","author":"H Myrick","year":"2000","unstructured":"Myrick H, Brady KT, Malcolm R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse. 2000;26(1):155-160. https:\/\/doi.org\/10.1081\/ada-100100597","journal-title":"Am J Drug Alcohol Abuse."},{"key":"9817_CR20","doi-asserted-by":"publisher","unstructured":"Lp L, T C, S H. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21(2). https:\/\/doi.org\/10.1300\/J069v21n02_05","DOI":"10.1300\/J069v21n02_05"},{"issue":"9","key":"9817_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/phar.2309","volume":"39","author":"AR Levine","year":"2019","unstructured":"Levine AR, Carrasquillo L, Mueller J, Nounou MI, Naut ER, Ibrahim D. High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis. Pharmacotherapy. 2019;39(9):881-888. https:\/\/doi.org\/10.1002\/phar.2309","journal-title":"Pharmacotherapy."},{"key":"9817_CR22","unstructured":"Premier Healthcare Database White Paper: Data that Informs and Performs. Accessed January 12, 2024. https:\/\/offers.premierinc.com\/rs\/381-NBB-525\/images\/PremierHealthcareDatabaseWhitepaper.pdf"},{"issue":"4","key":"9817_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa041895","volume":"353","author":"PK Lindenauer","year":"2005","unstructured":"Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative Beta-Blocker Therapy and Mortality after Major Noncardiac Surgery. N Engl J Med. 2005;353(4):349-361. https:\/\/doi.org\/10.1056\/NEJMoa041895","journal-title":"N Engl J Med."},{"issue":"8","key":"9817_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJMoa0707571","volume":"358","author":"S Schneeweiss","year":"2008","unstructured":"Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358(8):771-783. https:\/\/doi.org\/10.1056\/NEJMoa0707571","journal-title":"N Engl J Med."},{"key":"9817_CR25","doi-asserted-by":"publisher","unstructured":"Steel TL, Afshar M, Edwards S, et al. Research Needs for Inpatient Management of Severe Alcohol Withdrawal Syndrome: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 204(7):e61-e87. https:\/\/doi.org\/10.1164\/rccm.202108-1845ST","DOI":"10.1164\/rccm.202108-1845ST"},{"issue":"4","key":"9817_CR26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/npr2.12347","volume":"43","author":"D Malone","year":"2023","unstructured":"Malone D, Costin BN, MacElroy D, Al-Hegelan M, Thompson J, Bronshteyn Y. Phenobarbital versus benzodiazepines in alcohol withdrawal syndrome. Neuropsychopharmacol Rep. 2023;43(4):532-541. https:\/\/doi.org\/10.1002\/npr2.12347","journal-title":"Neuropsychopharmacol Rep."},{"issue":"2","key":"9817_CR27","doi-asserted-by":"publisher","first-page":"e13282","DOI":"10.7759\/cureus.13282","volume":"13","author":"F Hawa","year":"2021","unstructured":"Hawa F, Gilbert L, Gilbert B, et al. Phenobarbital Versus Lorazepam for Management of Alcohol Withdrawal Syndrome: A Retrospective Cohort Study. Cureus. 2021;13(2):e13282. https:\/\/doi.org\/10.7759\/cureus.13282","journal-title":"Cureus."},{"issue":"2","key":"9817_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jama.278.2.144","volume":"278","author":"MF Mayo-Smith","year":"1997","unstructured":"Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278(2):144-151. https:\/\/doi.org\/10.1001\/jama.278.2.144","journal-title":"JAMA"},{"issue":"9662","key":"9817_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","volume":"373","author":"MA Schuckit","year":"2009","unstructured":"Schuckit MA. Alcohol-use disorders. The Lancet. 2009;373(9662):492-501. https:\/\/doi.org\/10.1016\/S0140-6736(09)60009-X","journal-title":"The Lancet."},{"key":"9817_CR30","unstructured":"Benzodiazepine Equivalents Conversion Calculator - ClinCalc.com. Accessed January 12, 2024. https:\/\/clincalc.com\/Benzodiazepine\/"},{"issue":"7","key":"9817_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.10.004","journal-title":"J Clin Epidemiol."},{"key":"9817_CR32","unstructured":"U.S. Census Divisions | Geographical Reference Maps | National Centers for Environmental Information (NCEI). Accessed November 10, 2024. https:\/\/www.ncei.noaa.gov\/access\/monitoring\/reference-maps\/us-census-divisions"},{"issue":"1","key":"9817_CR33","doi-asserted-by":"publisher","first-page":"e8694","DOI":"10.1371\/journal.pone.0008694","volume":"5","author":"M Rosvall","year":"2010","unstructured":"Rosvall M, Bergstrom CT. Mapping Change in Large Networks. PLoS ONE. 2010;5(1):e8694. https:\/\/doi.org\/10.1371\/journal.pone.0008694","journal-title":"PLoS ONE."},{"issue":"4","key":"9817_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/jech.2004.029454","volume":"60","author":"J Merlo","year":"2006","unstructured":"Merlo J, Chaix B, Ohlsson H, et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health. 2006;60(4):290-297. https:\/\/doi.org\/10.1136\/jech.2004.029454","journal-title":"J Epidemiol Community Health."},{"key":"9817_CR35","doi-asserted-by":"publisher","unstructured":"R S, Ls F, Mf MS. Alcohol withdrawal: a nationwide survey of inpatient treatment practices. J Gen Intern Med. 1995;10(9). https:\/\/doi.org\/10.1007\/BF02602395","DOI":"10.1007\/BF02602395"},{"issue":"3","key":"9817_CR36","first-page":"158","volume":"43","author":"Y Mo","year":"2018","unstructured":"Mo Y, Thomas MC, Laskey CS, Shcherbakova N, Bankert ML, Halloran RH. Current Practice Patterns in the Management Of Alcohol Withdrawal Syndrome. Pharm Ther. 2018;43(3):158-162.","journal-title":"Pharm Ther."},{"issue":"4","key":"9817_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-015-0358-1","volume":"75","author":"A Mirijello","year":"2015","unstructured":"Mirijello A, D\u2019Angelo C, Ferrulli A, et al. IDENTIFICATION AND MANAGEMENT OF ALCOHOL WITHDRAWAL SYNDROME. Drugs. 2015;75(4):353-365. https:\/\/doi.org\/10.1007\/s40265-015-0358-1","journal-title":"Drugs."},{"key":"9817_CR38","unstructured":"Ghiasi N, Bhansali RK, Marwaha R. Lorazepam. In: StatPearls. StatPearls Publishing; 2024. Accessed November 11, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532890\/"},{"issue":"2","key":"9817_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.mayocpiqo.2021.11.010","volume":"6","author":"TL Steel","year":"2022","unstructured":"Steel TL, Malte CA, Bradley KA, Hawkins EJ. Benzodiazepine Treatment and Hospital Course of Medical Inpatients With Alcohol Withdrawal Syndrome in the Veterans Health Administration. Mayo Clin Proc Innov Qual Outcomes. 2022;6(2):126-136. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2021.11.010","journal-title":"Mayo Clin Proc Innov Qual Outcomes."},{"issue":"11","key":"9817_CR40","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1177\/0885066619847119","volume":"35","author":"D Buell","year":"2020","unstructured":"Buell D, Filewod N, Ailon J, Burns KEA. Practice Patterns in the Treatment of Patients With Severe Alcohol Withdrawal: A Multidisciplinary, Cross-Sectional Survey. J Intensive Care Med. 2020;35(11):1250-1256. https:\/\/doi.org\/10.1177\/0885066619847119","journal-title":"Cross-Sectional Survey. J Intensive Care Med."},{"key":"9817_CR41","doi-asserted-by":"publisher","unstructured":"Zakhary K, Bruno S, Myatt CA, et al. Prevalence and Predictors of Non-Benzodiazepine Use in Patients with Alcohol Withdrawal Syndrome in United States Emergency Departments - a cross-sectional study. Innov Pharm. 2024;15(3). https:\/\/doi.org\/10.24926\/iip.v15i3.6270","DOI":"10.24926\/iip.v15i3.6270"},{"key":"9817_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.genhosppsych.2020.08.008","volume":"67","author":"SR Beach","year":"2020","unstructured":"Beach SR, Gross AF, Hartney KE, Taylor JB, Rundell JR. Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use. Gen Hosp Psychiatry. 2020;67:42-50. https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.08.008","journal-title":"Gen Hosp Psychiatry."},{"issue":"7","key":"9817_CR43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1358\/dot.2003.39.7.799445","volume":"39","author":"D Hedges","year":"2003","unstructured":"Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today Barc Spain 1998. 2003;39(7):551-557. https:\/\/doi.org\/10.1358\/dot.2003.39.7.799445","journal-title":"Drugs Today Barc Spain 1998"},{"key":"9817_CR44","unstructured":"Rahman S, Marwaha R. Haloperidol. In: StatPearls. StatPearls Publishing; 2024. Accessed November 11, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560892\/"},{"issue":"6","key":"9817_CR45","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/00003246-200006000-00014","volume":"28","author":"C McCowan","year":"2000","unstructured":"McCowan C, Marik P. Refractory delirium tremens treated with propofol: A case series. Crit Care Med. 2000;28(6):1781.","journal-title":"Crit Care Med."},{"issue":"5","key":"9817_CR46","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/emj.2003.007526","volume":"21","author":"K Subramaniam","year":"2004","unstructured":"Subramaniam K, Gowda RM, Jani K, Zewedie W, Ute R. Propofol combined with lorazepam for severe poly substance misuse and withdrawal states in intensive care unit: a case series and review. Emerg Med J. 2004;21(5):632-634. https:\/\/doi.org\/10.1136\/emj.2003.007526","journal-title":"Emerg Med J."},{"issue":"10","key":"9817_CR47","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1513\/AnnalsATS.202105-591ED","volume":"18","author":"TL Steel","year":"2021","unstructured":"Steel TL, Bradley KA. Improving Care for Inpatient Alcohol Withdrawal Syndrome: Addressing the Lack of Rigorous Research on a Common Condition. Ann Am Thorac Soc. 2021;18(10):1622-1623. https:\/\/doi.org\/10.1513\/AnnalsATS.202105-591ED","journal-title":"Ann Am Thorac Soc."},{"issue":"1","key":"9817_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/10550490500419110","volume":"15","author":"JJ Mariani","year":"2006","unstructured":"Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006;15(1):76-84. https:\/\/doi.org\/10.1080\/10550490500419110","journal-title":"Am J Addict."},{"key":"9817_CR49","doi-asserted-by":"crossref","unstructured":"Sanson-Fisher RW. Diffusion of innovation theory for clinical change. Med J Aust. 2004;180(6). Accessed October 12, 2024. https:\/\/www.mja.com.au\/journal\/2004\/180\/6\/diffusion-innovation-theory-clinical-change","DOI":"10.5694\/j.1326-5377.2004.tb05947.x"},{"key":"9817_CR50","doi-asserted-by":"publisher","unstructured":"S N, M N, A L, et al. Phenobarbital for Acute Alcohol Withdrawal Management in Surgical Trauma Patients-A Retrospective Comparison Study. Psychosomatics. 2020;61(4). https:\/\/doi.org\/10.1016\/j.psym.2020.01.008","DOI":"10.1016\/j.psym.2020.01.008"},{"key":"9817_CR51","doi-asserted-by":"publisher","unstructured":"Ronan MV, Ganatra RB, Saukkonen J. Establishing the safety of phenobarbital treatment of alcohol withdrawal syndrome on general medical wards: A retrospective cohort study. Alcohol Fayettev N. 2024;116:29-34. https:\/\/doi.org\/10.1016\/j.alcohol.2023.10.005","DOI":"10.1016\/j.alcohol.2023.10.005"},{"issue":"1","key":"9817_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","volume":"16","author":"P Pallmann","year":"2018","unstructured":"Pallmann P, Bedding AW, Choodari-Oskooei B, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):29. https:\/\/doi.org\/10.1186\/s12916-018-1017-7","journal-title":"BMC Med."},{"issue":"11","key":"9817_CR53","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353-1357. https:\/\/doi.org\/10.1111\/j.1360-0443.1989.tb00737.x","journal-title":"Br J Addict."},{"issue":"12","key":"9817_CR54","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MLR.0000000000000824","volume":"55","author":"JW Sun","year":"2017","unstructured":"Sun JW, Rogers JR, Her Q, et al. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051. https:\/\/doi.org\/10.1097\/MLR.0000000000000824","journal-title":"Med Care."},{"issue":"7","key":"9817_CR55","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","volume":"64","author":"JJ Gagne","year":"2011","unstructured":"Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.10.004","journal-title":"J Clin Epidemiol."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09817-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09817-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:25:41Z","timestamp":1774283141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09817-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["9817"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09817-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"The authors report no disclosures or conflicts of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate:"}}]}}